HDV RNA Levels and Progression of Hepatitis Delta Infection: A 14 Year Follow Up Experience in Italy

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Jul 6

PMID 37408247

Authors

Alessandra Mangia

Maria Maddalena Squillante

Filippo Fraticelli

Maria Chiara Cavorsi

Giulia Paroni

Lucia Zaffarano

Annarita Valeria Piazzolla

Affiliations

Soon will be listed here.

Abstract

Background: Identification of outcome predictors is one of the unmet needs in chronic HDV infection. Until recently, no reliable quantitative assays for HDV RNA were available.

Aims: To evaluate the impact of baseline viremia on natural history of HDV infection in a cohort of patients whose serum samples were stored at their first visit 15 years ago.

Methods: Quantitative HBsAg, HBeAg, HBeAb, HBV DNA, HDV RNA, genotypes, and liver disease severity were assessed at baseline. Patients who were no longer on active follow-up were recalled and re-evaluated in August 2022.

Results: The majority of patients were male (64.9%); the median age was 50.1 years; and all patients were Italian, with only three born in Romania. All were HBeAg negative with HBV genotype D infection. Patients were subdivided three groups: 23 were in active follow-up (Group 1), 21 were recalled due to no longer being in follow-up (Group 2), and 11 died (Group 3). Liver cirrhosis was diagnosed in 28 subjects at the first visit; 39.3% of diagnosed patients were in Group 3, 32.1% were in Group 1 and 28.6% were in Group 2 ( = 0.001). Baseline HBV DNA IU/mL Log10 were 1.6 (1.0-5.9) in Group 1, 1.3 (1.0-4.5) in Group 2, and 4.1 (1.5-4.5) in Group 3; median baseline HDV RNA Log10 levels were 4.1 (0.7-6.7) in Group 1, 3.2 (0.7-6.2) in Group 2, and 5.2 (0.7-6.7) in Group 3, resulting significantly higher rates among patients in Group 3 compared to the other groups ( = 0.038). Eighteen patients in Group 2, as compared to 7 in Group 1, had undetectable HDV RNA at the follow-up evaluation ( = 0.001).

Conclusions: HDV chronic infection is a heterogeneous disease. It may not only progress but also improve over time in patients, who eventually become HDV RNA-undetectable. HDV RNA levels may help identify the subgroup of patients with less progressive liver disease.

References

Kamal H, Westman G, Falconer K, Duberg A, Weiland O, Haverinen S . Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology. 2020; 72(4):1177-1190. DOI: 10.1002/hep.31214. View

Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni A, Scioscia R . Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004; 126(7):1740-9. DOI: 10.1053/j.gastro.2004.03.017. View

Le Gal F, Gault E, Ripault M, Serpaggi J, Trinchet J, Gordien E . Eighth major clade for hepatitis delta virus. Emerg Infect Dis. 2006; 12(9):1447-50. PMC: 3294742. DOI: 10.3201/eid1209.060112. View

Le Gal F, Brichler S, Sahli R, Chevret S, Gordien E . First international external quality assessment for hepatitis delta virus RNA quantification in plasma. Hepatology. 2016; 64(5):1483-1494. DOI: 10.1002/hep.28772. View

Stockdale A, Kreuels B, Henrion M, Giorgi E, Kyomuhangi I, de Martel C . The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020; 73(3):523-532. PMC: 7438974. DOI: 10.1016/j.jhep.2020.04.008. View

Heidrich B, Yurdaydin C, Kabacam G, Ratsch B, Zachou K, Bremer B . Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014; 60(1):87-97. DOI: 10.1002/hep.27102. View

Vlachogiannakos J, Papatheodoridis G . New epidemiology of hepatitis delta. Liver Int. 2020; 40 Suppl 1:48-53. DOI: 10.1111/liv.14357. View

Ricco G, Popa D, Cavallone D, Iacob S, Salvati A, Tabacelia D . Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection. J Viral Hepat. 2018; 25(8):911-919. DOI: 10.1111/jvh.12895. View

Scheller L, Hilgard G, Anastasiou O, Dittmer U, Kahraman A, Wedemeyer H . Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. Medicine (Baltimore). 2021; 100(28):e26571. PMC: 8284709. DOI: 10.1097/MD.0000000000026571. View

10.

Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D . High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One. 2014; 9(3):e92062. PMC: 3962389. DOI: 10.1371/journal.pone.0092062. View

11.

Stroffolini T, Morisco F, Ferrigno L, Pontillo G, Iantosca G, Cossiga V . Acute Delta Hepatitis in Italy spanning three decades (1991-2019): Evidence for the effectiveness of the hepatitis B vaccination campaign. J Viral Hepat. 2021; 29(1):78-86. DOI: 10.1111/jvh.13620. View

12.

Wu J, Chen T, Huang Y, Yen F, Ting L, Sheng W . Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology. 1995; 108(3):796-802. DOI: 10.1016/0016-5085(95)90453-0. View

13.

Yurdaydin C, Idilman R, Bozkaya H, Bozdayi A . Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010; 17(11):749-56. DOI: 10.1111/j.1365-2893.2010.01353.x. View

14.

Ferenci P, Formann E, Romeo R . Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a. Am J Gastroenterol. 2005; 100(7):1626-7. DOI: 10.1111/j.1572-0241.2005.50006_10.x. View

15.

Wranke A, Pinheiro Borzacov L, Parana R, Lobato C, Hamid S, Ceausu E . Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). Liver Int. 2017; 38(5):842-850. DOI: 10.1111/liv.13604. View

16.

Rosina F, Conoscitore P, Cuppone R, Rocca G, Giuliani A, Cozzolongo R . Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology. 1999; 117(1):161-6. DOI: 10.1016/s0016-5085(99)70563-9. View

17.

Roche B, Samuel D . Liver transplantation in delta virus infection. Semin Liver Dis. 2012; 32(3):245-55. DOI: 10.1055/s-0032-1323630. View

18.

Abdrakhman A, Ashimkhanova A, Almawi W . Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis. Antiviral Res. 2020; 185:104995. DOI: 10.1016/j.antiviral.2020.104995. View

19.

Stelzl E, Ciesek S, Cornberg M, Maasoumy B, Heim A, Chudy M . Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. J Clin Virol. 2021; 142:104932. DOI: 10.1016/j.jcv.2021.104932. View

20.

Martini S, Tandoi F, Romagnoli R, Rizzetto M . Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients. Transplantation. 2022; 106(10):1935-1939. DOI: 10.1097/TP.0000000000004138. View